Patents Examined by Amanda L Aguirre
  • Patent number: 10590087
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: March 17, 2020
    Assignee: Pfizer Inc.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 10590100
    Abstract: The present application discloses 2-phenyl benzofuran derivative compounds and compositions, and methods for treating ocular diseases, neurological disorders and protein aggregation-related disorders in patients using the compounds and compositions as disclosed herein.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: March 17, 2020
    Assignee: AMBIENT PHOTONICS, INC.
    Inventors: John C. Warner, Srinivasa R. Cheruku, Jeffery A. Gladding
  • Patent number: 10573823
    Abstract: An organic electroluminescence device including: an anode; a cathode; two or more emitting units that are disposed between the anode and the cathode, each unit having an emitting layer; and a charge-generating layer that is disposed between the emitting units, wherein the charge-generating layer includes an N layer nearer to the anode and a P layer nearer to the cathode, and the N layer includes a compound represented by the following formula (I) or (II):
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: February 25, 2020
    Assignee: JOLED INC
    Inventors: Emiko Kambe, Masato Nakamura, Masakazu Funahashi, Hiroshi Yamamoto, Sayaka Mizutani
  • Patent number: 10561652
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 18, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Patent number: 10548884
    Abstract: This invention relates to compounds that are agonists of the muscarinic M4 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R1, R2, R3, R9 and R4 are as defined herein.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 4, 2020
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Mark David Rackham, Benjamin Gerald Tehan
  • Patent number: 10538523
    Abstract: The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They may useful in the treatment of a number of conditions, including pain and epilepsy.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 21, 2020
    Assignee: PFIZER LIMITED
    Inventors: Kevin Neil Dack, Robert McKenzie Owen, David Cameron Pryde
  • Patent number: 10533026
    Abstract: The invention relates to degradation of organophosphate neurotoxins with molybdenum complexes. In particular, the degradation of phosphate ester neurotoxins can be performed with molybdenum peroxo complexes resulting in recoverable phosphorus-containing compounds.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: January 14, 2020
    Assignee: Lewis & Clark College
    Inventor: Louis Kuo
  • Patent number: 10526320
    Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
  • Patent number: 10519107
    Abstract: The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: December 31, 2019
    Assignee: The Governing Council of the University of Toronto
    Inventors: Patrick Thomas Gunning, Abbarna A. Cumaraswamy, Andrew Martin Lewis, Mulu Geletu-Heye
  • Patent number: 10502737
    Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: December 10, 2019
    Assignee: The University of Vermont And State Agriculture College
    Inventor: David Schneider
  • Patent number: 10494355
    Abstract: The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: December 3, 2019
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Yuntae Kim, Chang Sik Lee, Jung Taek Oh, Hyeseung Song, Jin Choi, Jaeyoung Lee
  • Patent number: 10487020
    Abstract: A process involving admixing a ligand and an alkanolamine. The process allows the use of ligand despite the presence of contaminating amounts of phosphorus acid, and improves the shelf life of premixed ligand solutions.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 26, 2019
    Assignee: Dow Technology Investments LLC
    Inventors: Michael A. Brammer, George R. Phillips, Glenn A. Miller, Donald L. Campbell, Jr.
  • Patent number: 10487074
    Abstract: The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: November 26, 2019
    Assignee: HANLIM PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Chun Ryu, Yong-Kyun Park, Hyun-Kyu Kim, Dong-Yeop Shin
  • Patent number: 10479782
    Abstract: The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: November 19, 2019
    Assignee: Mylan Laboratories Limited
    Inventors: Ramakoteswara Rao Jetti, Hemant Malhari Mande, AnJaneyaraju Indukuri, Bommareddy Aggiramireddy, Neelima Bhagavatula, Amit Singh, Soumyajit Ghosh, Attanti Veera Venkata Srinivasarao, Umasankara Sastry Tummalapalli, Veera Venkata Satya Surya Appala Gosula
  • Patent number: 10479798
    Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 19, 2019
    Assignees: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Honglin Li, Hualiang Jiang, Yufang Xu, Jia Li, Zhenjiang Zhao, Jingya Li, Hongling Xu, Shiliang Li
  • Patent number: 10472354
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10472328
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 12, 2019
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10464874
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: November 5, 2019
    Assignee: Merck Patent GmbH
    Inventors: Reiner Friedrich, Julian Osthoff
  • Patent number: 10464894
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 5, 2019
    Assignee: Redwood Biosciences, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Patent number: 10450309
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Merch Sharp & Dohme Corp.
    Inventors: Yongxin Han, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer